| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Revance Therapeutics, Inc. | Director | Common Stock | 0 | $0 | $3.65 | 06 Feb 2025 | Direct |
| Revance Therapeutics, Inc. | Director | Stock Option (Right to buy) | 23,458 | 01 May 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000095017025015353-kolaja-carey-oconnor-2025-02-04 | Revance Therapeutics, Inc. | 04 Feb 2025 | 2 | -$60,448 | 4 | Director | 06 Feb 2025, 15:56 |
| /report/000147929024000087-kolaja-carey-oconnor-2024-05-01 | Revance Therapeutics, Inc. | 01 May 2024 | 2 | $0 | 4 | Director | 03 May 2024, 08:45 |
| /report/000147929023000080-kolaja-carey-oconnor-2023-06-15 | Revance Therapeutics, Inc. | 15 Jun 2023 | 3 | -$25,300 | 4 | Director | 20 Jun 2023, 16:25 |
| /report/000147929023000061-kolaja-carey-oconnor-2023-05-03 | Revance Therapeutics, Inc. | 03 May 2023 | 2 | $0 | 4 | Director | 05 May 2023, 17:14 |
| /report/000147929022000066-kolaja-carey-oconnor-2022-05-04-restatement | Revance Therapeutics, Inc. | 04 May 2022 | 1 | $0 | 4/A | Director | 13 May 2022, 18:10 |
| /report/000147929021000110-kolaja-carey-oconnor-2021-05-05 | Revance Therapeutics, Inc. | 05 May 2021 | 2 | $0 | 4 | Director | 07 May 2021, 19:08 |